{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:59:08Z","timestamp":1760385548302},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In sub-Saharan Africa (SSA), severe febrile illness accounts for a large majority of medical admissions. SSA patients may also suffer from cachexia and organ dysfunction resulting from tuberculosis, hepatitis B, and hypertension. It is hard to tell how these conditions influence the pharmacokinetics (PK) of antibiotics in this population. The aim of this systematic review was to summarize antibiotic PK data of SSA adult patient populations to clarify whether inappropriate drug concentrations that may also lead to antimicrobial resistance are likely to occur.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An electronic search was conducted in Ovid MEDLINE, Embase, and the African Index Medicus collecting studies from 1946 to May 2016. Reviewers independently selected studies reporting outcome data on volume of distribution (V), clearance, and half-life. Relevant information was abstracted and quality assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twelve studies were selected, addressing 6 antibiotic classes. There were 6 studies on fluoroquinolones and 1 on \u03b2-lactam antibiotics. Nine out of 12 originated from South Africa and 6 of those dealt with intensive care unit (ICU) populations. The quality of most studies was low. Studies on amikacin, teicoplanin, and ertapenem (n = 4) displayed a pattern of a large V with low drug concentrations. Fluoroquinolone PK changes were less prominent and more diverse whereas the probability of pharmacodynamic target attainment was low for the treatment of tuberculosis in South Africa. Interindividual variability of V was high for 10\/12 studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Antibiotic PK data of SSA adult patient populations are scarce, but disease-induced inappropriate drug concentrations do occur. Data from non\u2013ICU, severely ill patients, and \u03b2-lactam data are particularly lacking, whereas \u03b2-lactam antibiotics are commonly used, and typically vulnerable to disease-induced PK changes. Studies investigating the PK and pharmacodynamics of \u03b2-lactam antibiotics in severely ill, adult SSA patient populations are needed to improve local antibiotic dosing strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000418","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T13:53:07Z","timestamp":1495029187000},"page":"387-398","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics of Antibiotics in Sub-Saharan African Patient Populations: A Systematic Review"],"prefix":"10.1097","volume":"39","author":[{"given":"Jeannet C.","family":"Bos","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Centre, University of Amsterdam; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinier M.","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Division of Clinical Pharmacology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Centre, University of Amsterdam; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13054-015-0795-y","article-title":"Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systemic review and meta-analysis","volume":"19","author":"Marquet","year":"2015","journal-title":"Crit Care."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1128\/AAC.00627-10","article-title":"Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis","volume":"54","author":"Paul","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"e79603","DOI":"10.1371\/journal.pone.0079603","article-title":"Pharmacokinetics of drugs in cachectic patients: a systematic review","volume":"8","author":"Trobec","year":"2013","journal-title":"PLoS One"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"e2269","DOI":"10.1097\/MD.0000000000002269","article-title":"HIV-related medical admissions to a South African district hospital remain frequent despite effective antiretroviral therapy scale-up","volume":"94","author":"Meintjes","year":"2015","journal-title":"Medicine"},{"key":"R7-20230814","first-page":"e92131","article-title":"Etiology of severe febrile illness in low- and middle-income countries: a systematic review","volume":"9","author":"Prasad","year":"2014","journal-title":"PLoS One."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/S2214-109X(14)70002-6","article-title":"The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis","volume":"2","author":"Stanifer","year":"2014","journal-title":"Lancet Glob Health."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/liv.12884","article-title":"Health disparities in liver disease in sub-Saharan Africa","volume":"35","author":"Spearman","year":"2015","journal-title":"Liver Int."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"e0144944","DOI":"10.1371\/journal.pone.0144944","article-title":"High mortality from blood stream infection in Addis Ababa, Ethiopia, is due to antimicrobial resistance","volume":"10","author":"Seboxa","year":"2015","journal-title":"PLoS One"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/jac\/dku176","article-title":"Antimicrobial drug resistance among clinically relevant bacterial isolates in sub-Saharan Africa: a systematic review","volume":"69","author":"Leopold","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of finding tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0310057X9302100206","article-title":"Aminoglycoside volume of distribution and illness severity in critically ill septic patients","volume":"21","author":"Marik","year":"1993","journal-title":"Anaesth Intens Care."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01712162","article-title":"Fluctuation of the volume of distribution of amikacin and its effect on once daily dosage and clearance in a seriously ill patient","volume":"22","author":"Botha","year":"1996","journal-title":"Intensive Care Med."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/AAC.42.9.2235","article-title":"Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis","volume":"42","author":"Lipman","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijantimicag.2005.04.005","article-title":"Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis","volume":"26","author":"Gous","year":"2005","journal-title":"Int J Antimicrob Agents."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1128\/AAC.00048-12","article-title":"Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis","volume":"56","author":"Chigutsa","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00404-12","article-title":"Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentin","volume":"56","author":"Zvada","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.01478-13","article-title":"Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients","volume":"58","author":"Zvada","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1128\/AAC.00479-13","article-title":"Evaluation of initial and steady state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using Monte Carlo simulations","volume":"57","author":"Smythe","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijantimicag.2015.01.015","article-title":"Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis","volume":"45","author":"Brink","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijantimicag.2008.10.005","article-title":"Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis","volume":"33","author":"Brink","year":"2009","journal-title":"Int J Antimicrob Agents."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01061421","article-title":"Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria","volume":"34","author":"Pieters","year":"1988","journal-title":"Eur J Clin Pharmacol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1989.tb05359.x","article-title":"Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol","volume":"27","author":"Stein","year":"1989","journal-title":"Br J Clin Pharmacol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijantimicag.2014.09.006","article-title":"First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients","volume":"45","author":"Blackburn","year":"2015","journal-title":"Int J Antimicrob Agents."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2013.04.021","article-title":"Evaluating amikacin dosage regimens in intensive car unit patients: a pharmacokinetic\/pharmacodynamics analysis using Monte Carlo simulation","volume":"42","author":"Zazo","year":"2013","journal-title":"Int J Antimicrob Agents."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00134-002-1313-7","article-title":"Experience with a once-daily dosing program of aminoglycosides in critically ill patients","volume":"28","author":"Buijk","year":"2002","journal-title":"Intensive Care Med."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40264-013-0031-0","article-title":"Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk","volume":"36","author":"Boyer","year":"2013","journal-title":"Drug Saf."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/dkl485","article-title":"Ertapenem in critically ill patients with early onset ventilator-associated pneumonia: pharmacokinetics with special consideration for free-drug concentration","volume":"59","author":"Burkhardt","year":"2007","journal-title":"J Antimicrob Chemother."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/01.ftd.0000249942.14145.ff","article-title":"Teicoplanin population pharmacokinetics analysis in hospitalized patients","volume":"28","author":"Soy","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s11096-016-0308-3","article-title":"Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis","volume":"38","author":"Nakano","year":"2016","journal-title":"Int J Clin Pharm."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentration of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"503","DOI":"10.5588\/09640569513011","article-title":"Ofloxacin population pharmacokinetics in patients with tuberculosis","volume":"6","author":"Stambaugh","year":"2002","journal-title":"Int J Tuberc Lung Dis."},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jac\/dkt040","article-title":"Population pharmacokinetics and pharmacodynamics evaluation of intravenous and enteral moxifloxacin in surgical intensive care patients","volume":"68","author":"Kees","year":"2013","journal-title":"J Antimicrob Chemother."},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/jac\/dkr220","article-title":"Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations","volume":"66","author":"Khachman","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijantimicag.2008.05.019","article-title":"Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamics approaches","volume":"32","author":"Conil","year":"2008","journal-title":"Int J Antimicrob Agents."},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/38.1.103","article-title":"Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects","volume":"38","author":"Shah","year":"1996","journal-title":"J Antimicrob Chemother."},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/40.1.91","article-title":"Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever","volume":"40","author":"Acharya","year":"1997","journal-title":"J Antimicrob Chemother."},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data","volume":"14","author":"Van Boeckel","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"R48-20230814","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients","volume":"6","author":"Minichmayr","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R49-20230814","first-page":"w14368","article-title":"Prolonged administration of \u03b2-lactam antibiotics \u2013 a comprehensive review and critical appraisal","volume":"146","author":"Osthoff","year":"2016","journal-title":"Swiss Med Wkly."},{"key":"R50-20230814","doi-asserted-by":"crossref","first-page":"e0149310","DOI":"10.1371\/journal.pone.0149310","article-title":"Development of antibiotic resistance during simulated treatment of Pseudomonas aeroginosa in chemostats","volume":"11","author":"Feng","year":"2016","journal-title":"PLoS One"},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/cit596","article-title":"Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review","volume":"58","author":"Huson","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R52-20230814","first-page":"50","article-title":"Strategies for the prevention and containment of antibiotic resistance","volume":"48","author":"Essack","year":"2006","journal-title":"SA Fam Pract."},{"key":"R53-20230814","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review","volume":"38","author":"Sime","year":"2012","journal-title":"Ann Intensive Care."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:12:21Z","timestamp":1692051141000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201708000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000418","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}